BridgeBio launches secondary offering of 5,000,000 shares by KKR Genetic Disorder LP - BBIO News | RalliesBridgeBio launches secondary offering of 5,000,000 shares by KKR Genetic Disorder LP
B
BBIO• BridgeBio secondary offering details
- BridgeBio launched a secondary public offering of 5,000,000 common shares sold by KKR Genetic Disorder L.P.
- No shares are being sold by BridgeBio; no proceeds will go to the company.
- William Blair, Goldman Sachs, KKR to act as joint book-running managers; deal terms depend on market conditions.
- Shares will be offered under BridgeBio’s Form S-3ASR automatic shelf registration statement, effective July 24, 2026.
